Covid Nasal Spray
-
{
- All
- News
-
Nasal Spray Lowers Covid Viral Load By 94% In 24 Hours: Lancet Study
A nasal spray administered in high-risk adult Covid patients in India reduced viral load by 94% within 24 hours and 99% in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
-
Nasal Spray Lowers Covid Viral Load By 94% In 24 Hours: Lancet Study
A nasal spray administered in high-risk adult Covid patients in India reduced viral load by 94% within 24 hours and 99% in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
